Characterization of the anti-tumor immune response in human cancers and strategies for immunotherapy

Picker, 1992, Mechanisms of lymphocyte homing, Curr Opin Immunol, 4, 277, 10.1016/0952-7915(92)90077-R Janeway, 1992, Lymphocyte activation and effector functions, Curr Opin Immunol, 4, 241, 10.1016/0952-7915(92)90071-L Liu, 1992, Costimulation of T-cell growth, Curr Opin Immunol, 4, 265, 10.1016/0952-7915(92)90075-P Mentzer, 1987, Sialophorin, a surface sialoglycoprotein defective in the Wiskott-Aldrich syndrome, is involved in human T-lymphocyte proliferation, J Exp Med, 161, 641 van Seventer, 1991, Roles of multiple accessory molecules in T-cell activation, Curr Opin Immunol, 3, 294, 10.1016/0952-7915(91)90027-X Rotteveel, 1989, Clonal analysis of functionally distinct human CD4+ T cell subsets, J Exp Med, 168, 1659, 10.1084/jem.168.5.1659 Meuer, 1982, Clonal analysis of human cytotoxic T lymphocytes: T4+ and T8+ effector T cells recognize products of different major histocompatibility complex regions, 79, 4395 Rudd, 1989, Molecular interactions, T-cell subsets and a role of the CD4CD8: p56 lck complex in human T-cell activation, Immunol Rev, 111, 225, 10.1111/j.1600-065X.1989.tb00548.x Janeway, 1989, The role of CD4 in T-cell activation: accessory molecule or co-receptor?, Immunol Today, 10, 234, 10.1016/0167-5699(89)90260-0 Wang, 1992, MHC-class-I-restricted auto-tumor-specific CD4+ CD8-T-cell clones established from autologous mixed lymphocyte-tumor-cell culture (MLTC), Int J Cancer, 51, 962, 10.1002/ijc.2910510621 Mitchel, 1991, Attempts to optimize active specific immunotherapy for melanomas, Int Rev Immunol, 7, 331, 10.3109/08830189109114878 Strassman, 1984, OKT4+ cytotoxic T cells can lyse targets via class I molecules and can be blocked by monoclonal antibody against T4 molecules, J Immunol, 133, 1705, 10.4049/jimmunol.133.4.1705 Thomas, 1988, Differential expression of the leucocyte common antigen family, Immunol Today, 9, 320, 10.1016/0167-5699(88)91326-6 Sanders, 1988, Human naive and memory T cells, Immunol Today, 9, 195, 10.1016/0167-5699(88)91212-1 Mackay, 1991, T-cell memory: the connection between function, phenotype and migration pathways, Immunol Today, 12, 189, 10.1016/0167-5699(91)90051-T Beverly, 1991, Immunological memory in T cells, Curr Opin Immunol, 3, 355, 10.1016/0952-7915(91)90038-3 Akbar, 1991, The synergy between naive and memory T cells during activation, Immunol Today, 12, 184, 10.1016/0167-5699(91)90050-4 Beverly, 1990, Is T-cell memory maintained by crossreactive stimulation?, Immunol Today, 11, 203, 10.1016/0167-5699(90)90083-L Rothstein, 1991, Cyclic regulation of CD45 isoform expression in a long term human CD4+CD45RA+ T cell line, J Immunol, 146, 1175, 10.4049/jimmunol.146.4.1175 Bell, 1990, Interconversions of CD45R subsets of CD4 T cells in vivo, Nature, 348, 163, 10.1038/348163a0 Salmon, 1989, Production of lymphokine mRNA by CD45R+ and CD45R-helper T cells from human peripheral blood and human CD4+ T cell clones, J Immunol, 143, 907, 10.4049/jimmunol.143.3.907 Sohen, 1990, The functional heterogeneity of CD8+ cells defined by anti-CD45RA (2H4) and anti-CD29 (4B4) antibodies, Cell Immunol, 128, 314, 10.1016/0008-8749(90)90028-P Yamashita, 1989, Phenotypic characterization of the past-thymic differentiation of human alloantigen-specific CD8+ cytotoxic T lymphocytes, J Immunol, 143, 1518, 10.4049/jimmunol.143.5.1518 Fujii, 1992, Reversal of CD45R isoform switching in CD8+ T cells, Cell Immunol, 139, 176, 10.1016/0008-8749(92)90110-B Okumura, 1993, Both CD45RA+ and CD45RA-subpopulations of CD8+ T cells contain cells with high levels of lymphocyte function-antigen-I expression, a phenotype of primed T cells, J Immunol, 150, 429, 10.4049/jimmunol.150.2.429 Jong, 1991, Human CD8+ T lymphocytes can be devided into CD45RA+ and CD45RO+ cells with different requirements for activation and differentiation, J Immunol, 146, 2088, 10.4049/jimmunol.146.7.2088 Chan, 1992, New insights into T-cell antigen receptor structure and signal transduction, Curr Opin Immunol, 4, 246, 10.1016/0952-7915(92)90072-M Clayton, 1992, T-cell-receptor isoforms, Int J Cancer, 1 Moretta, 1991, Molecular and cellular analysis of human T lymphocytes expressing γδ T-cell receptor, Immunol Rev, 120, 118 Koning, 1991, Lymphocyte antigen receptors: a common design?, Immunol Today, 12, 100, 10.1016/0167-5699(91)90091-7 Konig, 1990, The implications of subunit interactions for the structure of the T cell receptor-CD3 complex, Eur J Immunol, 20, 299, 10.1002/eji.1830200211 Orlof, 1990, Family of disulphide-linked dimers containing the zeta and eta chains of the T-cell receptor and the gamma chain of Fc receptors, Nature, 347, 189, 10.1038/347189a0 Kabelitz, 1990, A large fractions of human peripheral blood gamma/delta + T cells is activated by mycobacterium tuberculosis but not by its 65 KD heat shock protein, J Exp Med, 171, 667, 10.1084/jem.171.3.667 Rivas, 1989, Evidence for involvement of the γδ T cell antigen receptor in cytotoxicity mediated by human alloantigen specific T-cell clones, J Immunol, 142, 180, 10.4049/jimmunol.142.6.1840 Kabelitz, 1990, Human cytotoxic lymphocytes. V. Frequency and specificity of γδ+ cytotoxic lymphocyte precursors activated by allogeneic or autologous stimulatory cells, J Immunol, 145, 2827, 10.4049/jimmunol.145.9.2827 Fisch, 1990, γδ T cell-clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex restricted cytolysis, J Exp Med, 171, 1567, 10.1084/jem.171.5.1567 Fisch, 1992, MHC-unrestricted cytotoxic and proliferative responses of two distinct human γδ T cell subsets to Daudi cells, J Immunol, 148, 2315, 10.4049/jimmunol.148.8.2315 Sturm, 1990, Human Vγ9-Vδ2 T cell receptor-γδ lymphocytes show specificity to Burkitt's lymphoma cells, J Immunol, 145, 3202, 10.4049/jimmunol.145.10.3202 June, 1991, Signal transduction in T cells, Curr Opin Immunol, 3, 287, 10.1016/0952-7915(91)90026-W Liu, 1992, Costimulation of T-cell growth, Curr Opin Immunol, 4, 267, 10.1016/0952-7915(92)90075-P Shaw, 1988, Two molecular pathways of human T cell adhesion, Curr Opin Immunol, 1, 92, 10.1016/0952-7915(88)90058-1 Moingeon, 1989, CD2-mediated adhesion facilities T lymphocyte recognition function, Nature, 339, 312, 10.1038/339312a0 Springer, 1990, Adhesion receptors of the immune system, Nature, 346, 425, 10.1038/346425a0 Kuhlman, 1991, The accessory function of murine ICAM-1 in T lymphocyte activation, J Immunol, 146, 1773, 10.4049/jimmunol.146.6.1773 Dustin, 1989, T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1, Nature, 351, 619, 10.1038/341619a0 Mourad, 1990, Engagement of major histocompatibility complex class II molecules induces sustained, lymphocyte function-associated molecule 1-dependent cell adhesion, J Exp Med, 172, 1513, 10.1084/jem.172.5.1513 Kawakami, 1989, Requirement for delivery of signals by physical interaction and soluble factors from accessory cells in the induction of receptormediated T-cell proliferation, J Immunol, 142, 1818, 10.4049/jimmunol.142.6.1818 June, 1990, Role of the CD28 receptor in T-cell activation, Immunol Today, 11, 211, 10.1016/0167-5699(90)90085-N Koulova, 1991, The CD28 ligand B7BB1 provides costimulatory signal for alloactivation of CD4+ T cells, J Exp Med, 173, 759, 10.1084/jem.173.3.759 Jung, 1987, Induction of cytotoxicifty in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates, 84, 4611 Azuma, 1992, CD28 interaction with B7 co-stimulates primary allogeneic proliferative responses and cytotoxicity mediated by small resting T lymphocytes, J Exp Med, 175, 353, 10.1084/jem.175.2.353 Malefyt, 1993, CD2LFA-3 or LFA-1ICAM-1 but not CD28B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes, Eur J Immunol, 23, 418, 10.1002/eji.1830230218 Dang, 1990, Human CD4 helper T cell activation: Functional involvement of two distinct collagen receptors, IF7 and VLA integrin family, J Exp Med, 172, 649, 10.1084/jem.172.2.649 Shimizu, 1990, Regulated expression and function of three VLA (beta-1) integrin receptors on T cells, Nature, 345, 250, 10.1038/345250a0 Nojima, 1990, VLA-4 mediates CD3-dependent CD4+ T cell activation via the CS1 alternatively spliced domain of fibronectin, J Exp Med, 172, 1185, 10.1084/jem.172.4.1185 Yamada, 1991, Activation of human CD4 T lymphocytes. Interaction of fibronectin with VLA-5 receptor on CD4 cells induces the AP-1 transcription factor, J Immunol, 146, 53, 10.4049/jimmunol.146.1.53 Rudd, 1990, CD4, CD8 and TCR-CD3 complex: a novel class of protein tyrosine kinase receptor, Immunol Today, 11, 400, 10.1016/0167-5699(90)90159-7 June, 1991, Signal transduction in T cells, Curr Opin Immunol, 3, 287, 10.1016/0952-7915(91)90026-W June, 1990, Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation, J Immunol, 144, 1591, 10.4049/jimmunol.144.5.1591 Mustelin, 1990, T cell antigen receptor-mediated activation of phospholipase C requires tyrosine phosphorylation, Science, 247, 1584, 10.1126/science.2138816 Turka, 1992, CD45 modulates T cell receptor/CD3-induced activation of human thymocytes via regulation of tyrosine phosphorylation, Eur J Immunol, 22, 551, 10.1002/eji.1830220238 Biever, 1991, T cell receptors: adhesion and signalling, Adv Cancer Res, 56, 49, 10.1016/S0065-230X(08)60477-7 Koretzky, 1990, Tyrosine phosphatase CD45 is essential for coupling T-cell antigen receptor to the phosphatidyl inositol pathway, Nature, 346, 66, 10.1038/346066a0 Ledbetter, 1991, CD45 cross-linking regulates phospholipase of specific substrates in CD3Ti-stimulated T-cells, J Immunol, 146, 1577 Linsley, 1990, T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7BB-1, 87, 5031 Fraser, 1991, Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28, Science, 251, 313, 10.1126/science.1846244 Trinchieri, 1989, Biology of natural killer cells, Adv Immunol, 47, 187, 10.1016/S0065-2776(08)60664-1 Whiteside, 1990, Characteristics of natural killer cells and lymphokine-activated killer cells, Immunol Allergy Clin North Am, 10, 663 Maengaa, 1993, Expression of integrins and other adhesion molecules on NH cells; impact of IL-2 on short and long-term cultures, Int J Cancer, 63, 850, 10.1002/ijc.2910530524 Tan, 1993, Enhancement of natural killer activity by an antibody to CD44, J Immunol, 150, 812 Roncardo, 1991, Natural killer cell clones can efficiently process and present protein antigens, J Immunol, 147, 781 Ravetch, 1991, Fc receptors, Annu Rev Immunol, 9, 457, 10.1146/annurev.iy.09.040191.002325 Lotzova, 1989, Analysis of effector mechanisms in cancer, Curr Opin Immunol, 1, 904, 10.1016/0952-7915(89)90069-1 Lanier, 1991, Molecular and functional analysis of human natural killer cell-associated neural cell adhesion molecule (N-CAMCD56), J Immunol, 146, 4421 Edelman, 1988, Morphoregulatory molecules, Biochemistry, 27, 3533, 10.1021/bi00410a001 Cunningham, 1987, Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing, Science, 236, 799, 10.1126/science.3576199 Hemperly, 1990, Characterization of cDNA clones defining variant forms of human neural cell adhesion mole cule N-CAM, J Mol Neurosci, 2, 71, 10.1007/BF02876913 Lanier, 1986, The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NH cells and cytotoxic T lymphocytes, J Immunol, 136, 4480 Anderson, 1990, Fc gamma receptor type III (CD16) is included in zeta NK receptor complex expressed by human natural killer cells, 87, 2274 Letourneur, 1991, Characterization of the family of dimers associated with Fc receptors. (FcϵRI and FcγRIII), J Immunol, 147, 2652 Caligiuri, 1990, Functional sequences of interleukin-2 receptor expression in resting human lymphocytes: Identification of a novel natural killer cell subset with high affinity receptors, J Exp Med, 171, 1509, 10.1084/jem.171.5.1509 Baume, 1992, Differential responses to interleukin-2 define functionally distict subjects of human natural killer cells, Eur J Immunol, 22, 1, 10.1002/eji.1830220102 Siegel, 1987, The IL-2 receptor beta chain: role in mediating signals for LAK, NK, and proliferative activities, Science, 238, 75, 10.1126/science.3116668 Nagler, 1990, Constitutive expression of high affinity interleukin-2 receptors on human CD16-natural killer cells in vivo, J Exp Med, 171, 1527, 10.1084/jem.171.5.1527 Moretta, 1990, A novel surface antigen expressed by a subset of human CD3-CD16+ natural killer cells, J Exp Med, 171, 695, 10.1084/jem.171.3.695 Lebow, 1993, Killer cell recruitment and renewal capacity of purified cytolytic and noncytolytic human peripheral blood natural killer cell subsets, J Immunol, 150, 320 Kennedy, 1991, Shared structural and functional motifs for signal transduction in T lymphocytes and natural killer cells, 52 O'Shea, 1991, Engagement of the NK cell IgG Fc receptor results in tyrosine phosphorylation of the z chain, 88, 350 Stahls, 1992, Activation of natural killer cells via the FcγRIII (CD16) requires initial tyrosine phospharylation, Eur J Immunol, 22, 611, 10.1002/eji.1830220249 O'Shea, 1992, A role for protein tyrosine kinase activity in natural cytotoxicity as well as antibody-dependent cellular cytotoxicity, J Immunol, 148, 2497 Ting, 1991, Fcγ receptor signal transduction in natural killer cells, J Immunol, 147, 3122 Procopio, 1991, GTP-binding proteins transduce signals generated via human Fcγ receptor III A (CD16), J Immunol, 146, 3550 Inocuchi, 1990, Antigen receptor-mediated regulation of sustained polyphosphoinositide turnover in a human T cell line, J Biol Chem, 265, 5983, 10.1016/S0021-9258(19)39280-4 Mescher, 1992, Surface contact requirements for activation of cytotoxic T lymphocytes, J Immunol, 149, 2402 O'Bourke, 1992, Cytotoxic T-lymphocyte activation involves a cascade of signalling and adhesion events, Nature, 358, 253, 10.1038/358253a0 O'Bourke, 1990, Activated CD8 binding to class I protein mediated by the T-cell receptor results in signalling, Nature, 346, 187, 10.1038/346187a0 Melief, 1992, Tumor eradication by adoptive transfer of cytotoxic T lymphocytes, Adv Cancer Res, 58, 143, 10.1016/S0065-230X(08)60294-8 Roitt, 1991, The acquired immune response. II-Production of effectors, 129 Suzuki, 1991, Evidence for the involvement of CD56 molecules in alloantigen-specific recognition by human natural killer cells, J Exp Med, 173, 1451, 10.1084/jem.173.6.1451 Nakamura, 1991, Activation of natural killer clone upon target cell binding via CD2, Eur J Immunol, 21, 831, 10.1002/eji.1830210345 Renzo, 1991, The function of human NK cells is enhanced by β-glucan, a ligand of CR3 (CD11bCD18), Eur J Immunol, 21, 1755, 10.1002/eji.1830210726 Karlhofer, 1992, MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells, Nature, 358, 66, 10.1038/358066a0 Raulet, 1992, A sense of something missing, Nature, 358, 21, 10.1038/358021a0 Versteeg, 1992, NK cells and T cells: mirror images?, Immunol Today, 13, 244, 10.1016/0167-5699(92)90003-P Peltenburg, 1992, c-myc-induced natural killer cell sensitivity of human melanoma cells is reversed by HLA-B27 transfection, Eur J Immunol, 22, 2717, 10.1002/eji.1830221040 Gorelik, 1990, Increased sensitivity to MHC-nonrestricted lysis of BL6 melanoma cells by transfection with class I H-2kb gene, J Immunol, 145, 1621 Reiter, 1991, Resistance to NK cell-mediated cytotoxicity does not correlate with class I MHC antigen levels, Immunobiology, 183, 23, 10.1016/S0171-2985(11)80183-X Berke, 1991, T-cell-mediated cytotoxicity, Curr Opin Immunol, 3, 320, 10.1016/0952-7915(91)90031-U Kawasaki, 1992, Expression of perforin murine natural killer cells and cytotoxic T lymphocytes in vivo, Eur J Immunol, 22, 1215, 10.1002/eji.1830220516 Tschopp, 1990, Perforin-mediated target cell lysis by cytolytic T lymphocytes, Annu Rev Immunol, 8, 279, 10.1146/annurev.iy.08.040190.001431 Goldstein, 1987, Cytolytic T cell Melodrama, Nature, 327, 12, 10.1038/327012a0 Liu, 1989, Identification and characterization of a membrane-bound cytotoxin of murine cytolytic lymphocytes that is related to tumor necrosis factor/cachectin, 86, 3286 Fillipini, 1990, Ecto-ATPase activity in cytolytic T-lymphocytes, J Biol Chem, 265, 334, 10.1016/S0021-9258(19)40234-2 Tachinaba, 1992, Generation of a small cell lung cancer variant resistant to lymphokine-activated killer (LAK) cells: association with resistance to a LAK cell-derived cytostatic factor, Cancer Res, 52, 3310 Hersoh, 1989, Cytostatic and cytotoxic activity of lymphokine-activated killer cell phenomenon, Cancer Immunol Immunother, 30, 65, 10.1007/BF01665032 Greenberg, 1991, Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells, Adv Immunol, 49, 281, 10.1016/S0065-2776(08)60778-6 Jerome, 1991, Cytotoxic T lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells, Cancer Res, 51, 2908 Barnd, 1989, Specific major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells, 86, 7159 Jung, 1991, Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins, J Exp Med, 173, 273, 10.1084/jem.173.1.273 Peace, 1991, T cell recognition of transforming proteins encoded by mutated ras protooncogenes, J Immunol, 146, 2059 Chen, 1992, T-cell immunity to the joining region of P210 BCR-ABL protein, 89, 1468 Ioannides, 1991, Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells, J Immunol, 146, 1700 Hudziak, 1988, Amplified expression of the HER2erbB2 oncogene induces resistance to tumor necrosis factor in NIH-3T3 cells, 85, 5102 Lichtenstein, 1990, Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2neu oncogenes, Cancer Res, 50, 7364 Ioannides, 1993, T cell recognition of human tumors: Implications for molecular immunotherapy of cancer, Clin Immunol Immunopathol, 66, 91, 10.1006/clin.1993.1012 Ioannides, 1992, CTL clones isolated from ovarian tumor infliltrating lymphocytes can recognize peptides with sequences corresponding to the HER2neu gene product, FASEB J A, 2711 Knuth, 1989, Cytolytic T cell clones against an autologous human melanoma specificity study and definition of three antigens by immunoselection, 86, 2804 van den Eynde, 1989, Presence on a human melanoma of multiple antigens recognized by autologous CTL, Int J Cancer, 44, 634, 10.1002/ijc.2910440413 Topalian, 1990, Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes, J Immunol, 144, 4487 Boon, 1992, Toward a genetic analysis of tumor rejection antigens, Adv Cancer Res, 58, 177, 10.1016/S0065-230X(08)60295-X van der Bruggen, 1991, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, 254, 1643, 10.1126/science.1840703 Boon, 1993, Teaching the immune system to fight cancer, Sci Am, 266, 32, 10.1038/scientificamerican0393-82 van der Brugger, 1992, Molecular definition of tumor antigens recognized by T lymphocytes, Curr Opin Immunol, 4, 608, 10.1016/0952-7915(92)90035-D Allarena, 1988, Proliferative response of lymphocytes from cancer patients to autologous tumor cells, Cancer Immunol Immunother, 27, 69, 10.1007/BF00205761 Browning, 1992, MHC antigens and cancer implications for T-cell surveillance, Curr Opin Immunol, 4, 613, 10.1016/0952-7915(92)90036-E Anichini, 1989, Immune response to specific human tumors, Curr Opin Immunol, 1, 917, 10.1016/0952-7915(89)90072-1 Vanky, 1988, Importance of MHC antigen expression on solid tumors in the in vitro interaction with autologous blood lymphocytes, Cancer Immunol Immunother, 27, 213, 10.1007/BF00205442 Fossati, 1988, Proliferative and/or cytotoxic activity of lymphocyte clones to autologous human melanoma, Int J Cancer, 42, 239, 10.1002/ijc.2910420216 Cozzolino, 1987, Characterization of cells from invaded lymphnodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoroliferative response, J Exp Med, 166, 303, 10.1084/jem.166.2.303 Nomura, 1992, Functional analysis of mononuclear cells infiltrating into tumors, Int Immunol, 4, 407, 10.1093/intimm/4.3.407 Mukherji, 1990, T-cell clones that react against autologous human tumors, Immunol Rev, 116, 33, 10.1111/j.1600-065X.1990.tb00803.x Chakraborty, 1990, Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response, J Immunol, 145, 2359 Miescher, 1986, Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors, J Immunol, 136, 1899 Derynck, 1987, Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors, Cancer Res, 47, 707 Tada, 1991, Transforming growth factor -β- induced inhibition of T cell function, J Immunol, 146, 1077 Torr-Amione, 1990, A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immunesurveillance, 87, 1486 Yoshino, 1992, Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor, Cancer Res, 52, 775 Ebert, 1987, Characterization of an immunosuppressive factor derived from colon cancer cells, J Immunol, 138, 2161 Jones, 1980, Destruction of extracellular matrices containing phycoproteins elastin and collagen by metastatic human tumor cells, Cancer Res, 40, 3222 Hersey, 1983, Inhibition of interleukin-2 production by factors released from tumor cells, J Immunol, 131, 2837 Itoh, 1988, Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas, J Exp Med, 168, 1419, 10.1084/jem.168.4.1419 Topalian, 1989, Tumor-specific cytolysis by lymphocytes infiltrating human melanomas, J Immunol, 142, 3714 Topalian, 1990, Tumor infiltrating lymphocytes (TIL) evidence for specific immune reactions against growing cancers in mouse and man, 19 Finke, 1990, Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma, Cancer Res, 50, 2363 Nouri, 1991, Correlation between class I antigen expression and the ability to generate tumor infiltrating lymphocytes from bladder tumor biopsies, Br J Cancer, 64, 996, 10.1038/bjc.1991.454 Ebert, 1989, Characterization of activated lymphocytes in colon cancer, Clin Immunol Immunopathol, 50, 72, 10.1016/0090-1229(89)90223-7 Baxevanis, 1993, Comparison of immune parameters in patients with one or two primary malignant neoplasms, Nat Immun, 12, 41 Anastasopoulos, 1992, Monocyte disorders associated with T cell defects in patients with solid tumors, Anticancer Res, 12, 489 Baxevanis, 1993, Prothymosin α restores the depressed allogeneic cell-mediated lympholysis and natural-killer-cell activity in patients with cancer, Int J Cancer, 53, 264, 10.1002/ijc.2910530216 Kosmidis, 1992, The prognostic significance of immune changes in patients with renal cancer treated with interferon A2b, J Clin Oncol, 10, 1153, 10.1200/JCO.1992.10.7.1153 Topalian, 1987, Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials, J Immunol Methods, 102, 124, 10.1016/S0022-1759(87)80018-2 Yoo, 1990, Tumor-infiltrating lymphocytes from human colon carcinomas, Gastroenterology, 98, 259, 10.1016/0016-5085(90)90813-G Numata, 1991, Functional evaluation of tumor-infiltrating mononuclear cells, Cancer, 68, 1937, 10.1002/1097-0142(19911101)68:9<1937::AID-CNCR2820680916>3.0.CO;2-D Becker, 1993, Tumor-infiltrating lymphocytes in primary melanoma: functional consequences of differential IL-2 receptor expression, Clin Exp Immunol, 91, 121, 10.1111/j.1365-2249.1993.tb03365.x Ioannides, 1991, Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites, Cancer Res, 51, 4257 Baxevanis, 1993, Autologous tumor-specific T lymphocytes in breast cancer. Infiltration of interleukin-2-inducible cytotoxic T lymphocytes in primary tumors and pleural malignant effusions, Int J Cancer, 53, 264, 10.1002/ijc.2910530216 Platsoukas, 1991, Human autologous tumor-specific T cells in malignant melanoma, Cancer Metastasis Rev, 10, 151, 10.1007/BF00049412 Nishimura, 1991, Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity, Urol Int, 47, 83, 10.1159/000282260 Nishimura, 1986, Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes, Cell Immunol, 100, 149, 10.1016/0008-8749(86)90015-8 Anderson, 1987, Modification of natural killer activity of lymphocytes infiltrating human lung cancers, Cancer Immunol Immunother, 25, 65, 10.1007/BF00199303 Heo, 1987, Long-term interleukin-2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck, Cancer Res, 47, 6353 Miescher, 1987, Clonal and frequency analyses of tumor infiltrating lymphocytes from human solid tumors, J Immunol, 138, 4004 Borst, 1987, A T cell receptor γCD3 complex found on cloned functional lymphocytes, Nature, 325, 683, 10.1038/325683a0 Moingeou, 1987, A γ-chain complex forms a functional receptor on cloned human lymphocytes with natural killer-like activity, Nature, 325, 723, 10.1038/325723a0 Wright, 1989, Cytotoxic T lymphocytes specific for self tumor immunoglobulin express T cell receptor δ chain, J Exp Med, 169, 1557, 10.1084/jem.169.5.1557 Zocchi, 1990, Selective lysis of the autologous tumor by δTCS1+ γδ+ tumor-infiltrating lymphocytes from human lung carcinomas, Eur J Immunol, 20, 2685, 10.1002/eji.1830201224 Bachelez, 1992, TCR gamma delta bearing T lymphocytes infiltrating human primary cutaneous melanomas, J Invest Dermatol, 98, 369, 10.1111/1523-1747.ep12499808 Nanno, 1992, γδ T cell antigen receptors expressed on tumor-infiltrating lymphocytes from patients with solid tumors, Eur J Immunol, 22, 679, 10.1002/eji.1830220310 Belldegrun, 1989, Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy, J Immunol, 142, 4520 Ioannides, 1991, Selective usage of TCR V beta in tumor-pecific CTL lines isolated from ovarian tumor-associated lymphocytes, Anticancer Res, 11, 1919 Albertini, 1991, Analysis of T cell receptor β and γ genes from peripheral blood, regional lymphnode and tumor-infiltrating lymphocyte clones from melanoma patients, Cancer Immunol Immunother, 32, 325, 10.1007/BF01789051 Ferradini, 1992, Analysis of T-cell receptor αβ variability in lymphocytes infiltrating a melanoma metastasis, Cancer Res, 52, 4649 Heo, 1988, Role of Leu-19 (NKH-1)-positive effector cells in mediating autologous and allogeneic tumor cell lysis in rIL2-activated cultures of lymphocytes infiltrating human ovarian tumors, J Immunol, 140, 4042 Wang, 1989, Lymphocytes infiltrating human ovarian tumors: Synergy between tumor necrosis factor α and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes, Cancer Res, 49, 5979 Vaccarello, 1990, Sustained outgrowth of auto-tumor-reactive T lymphocytes form human ovarian carcinomas in the presence of tumor necrosis factor α and interleukin 2, Human Immunol, 28, 216, 10.1016/0198-8859(90)90022-H Ioannides, 1991, Lymphocytes infiltrating malignant ascites: Modulation of IL-2-induced proliferation by IL-4 and of selective increase in CD8+ T cells by TNF-α, Lymphokine Cytokine Res, 10, 307 Shimizu, 1991, Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors, Cancer Immunol Immunother, 32, 280, 10.1007/BF01789045 Kawakami, 1988, Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma, J Exp Med, 168, 2138, 10.1084/jem.168.6.2183 Baxevanis, 1994, Lymphocytes infiltrating ascitic fluid and pleural effusions of advanced cancer patients: Synergy between IL-2 and IL-1β or TNF-α in the selective increase of CD8+ effectors and autologous tumor-specific cytotoxicity, Br J Cancer Stolfi, 1992, Tumor necrosis factor alpha selectively enhances growth and cytotoxic activity of tumor infiltrating lymphocytes from human colorectal cancer, J Surg Res, 52, 39, 10.1016/0022-4804(92)90276-6 Balch, 1983, Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients, Ann Surg, 198, 192, 10.1097/00000658-198308000-00014 Monson, 1987, Lymphokine activated killer (LAK) cells in patients with gastrointenstinal cancer, Gut, 28, 1420, 10.1136/gut.28.11.1420 Naume, 1991, Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells, J Immunol, 147, 2208 Baxevanis, 1993, Elevated PGE2 production by monocytes is responsible for the depressed levels of natural killer (LAK) cell function in patients with breast cancer, Cancer, 72, 491, 10.1002/1097-0142(19930715)72:2<491::AID-CNCR2820720227>3.0.CO;2-1 Geller, 1991, Generation of lymphokine-activated killer activity in I cells. Possible regulatory circuits, J Immunol, 146, 3280 Kaufmann, 1991, Lymphokine-activated killer (LAK) cells: Interferon-γ synergizes with interleukin-2 to induce LAK cytotoxicity in homogenous leukemic preparations, Clin Immunol Immunopathol, 58, 278, 10.1016/0090-1229(91)90142-W Papamichail, 1992, Gamma-interferon enhances the cytotoxic activity of interleukin-2-induced peripheral blood lymphocyte (LAK) cells, tumor infiltrating lymphocytes (TIL), and effusion associated lymphocytes, J Chemother, 4, 387, 10.1080/1120009X.1992.11739197 Reiter, 1992, A dual anti-tumor effect of a combination of interferon-α or interleukin-2 and 5-Fluorouracil on natural killer (NK) cell-mediated cytotoxicity, Clin Immunol Immunopathol, 62, 103, 10.1016/0090-1229(92)90029-N Jackson, 1992, An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines, J Urol, 147, 207, 10.1016/S0022-5347(17)37198-7 Ellis, 1989, Induction of human lymphokine-activated killer cells by IFN-α and IFN-γ, J Immunol, 141, 2349 Chouaib, 1988, Generation of lymphokine-activated killer cells: Synergy between tumor necrosis factor and interleukin 2, 85, 6875 Matossian-Rogers, 1989, Tumour necrosis factor-alpha enhances the cytolytic and cytostatic capacity of interleukin-2 activated killer cells, Br J Cancer, 59, 573, 10.1038/bjc.1989.116 Takai, 1988, B-cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes, J Immunol, 140, 508, 10.4049/jimmunol.140.2.508 Smyth, 1991, Comparison of the effect of IL-2 and IL-6 on the lytic activity of purified human peripheral blood large granular lymphocytes, J Immunol, 146, 1380, 10.4049/jimmunol.146.4.1380 Luger, 1989, IFN-β2IL-6 augments the activity of human natural killer cells, J Immunol, 143, 1206, 10.4049/jimmunol.143.4.1206 Gallacher, 1990, Interleukin-6 enhances the induction of human lymphokine-activated killer cells, Cancer Immunol Immunother, 31, 49, 10.1007/BF01742495 Mule, 1992, Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice, J Immunol, 148, 2622, 10.4049/jimmunol.148.8.2622 Mule, 1992, Clinical application of IL6 in cancer therapy, Res Immunol, 143, 777, 10.1016/0923-2494(92)80023-E Spagnoli, 1993, On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine activated killer cell activity, Cell Immunol, 146, 391, 10.1006/cimm.1993.1035 Parkinson, 1990, Interleukin-2: Further progress through greater understanding, J Natl Cancer Inst, 82, 1374, 10.1093/jnci/82.17.1374 Kos, 1993, IL-2-independent activity of IL-7 in the generation of secondary antigen-specific cytotoxic T cell responses in vitro, J Immunol, 150, 387, 10.4049/jimmunol.150.2.387 Crump, 1989, Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine activated killer cells, Cancer Res, 49, 149 Fujiwara, 1992, Regulation of lymphokine-activated killer cell induction by human recombinant IL-1 receptor antagonist, J Immunol, 148, 2941, 10.4049/jimmunol.148.9.2941 Smyth, 1991, Regulation of lymphocyte-activated killer activity and poreforming protein gene expression on human peripheral blood CD8+ T Imyphocytes, J Immunol, 146, 3289, 10.4049/jimmunol.146.10.3289 Krishnaraj, 1991, Immunomodulation by 9-amino-1,2,3,4-tetrahydroacridine (THA): 1. Down regulation of natural cell-mediated-cytotoxicity in vitro, Immunopharmacology, 22, 69, 10.1016/0162-3109(91)90031-S Klein-Struckmeier, 1991, Modulation of natural and interleukin-2-induced tumor-cytolytic activities by the members of a protein family related to betathromboglobulin, Cancer Immunol Immunother, 34, 175, 10.1007/BF01742309 Guillon, 1989, Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumor cell lines, Br J Cancer, 59, 515, 10.1038/bjc.1989.106 Chakvaborty, 1991, Suppression of lymphokine-activated killer cell generation by tumor-infiltrating lymphocytes, Clin Immunol Immunopathol, 59, 407, 10.1016/0090-1229(91)90036-A Sone, 1988, Differential effects of recombinant interferons α,β, and γ on induction of human. lymphokine (IL-2)-activated killer activity, J Natl Cancer Inst, 80, 425, 10.1093/jnci/80.6.425 Rosenberg, 1992, The immunotherapy and gene therapy of cancer, J Clin Oncol, 10, 180, 10.1200/JCO.1992.10.2.180 Rosenberg, 1986, New approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes, Science, 233, 1318, 10.1126/science.3489291 Hauninen, 1991, Biological monitoring of low-dose interleukin-2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes, Cancer Res, 50, 6312 Janssen, 1992, Peripheral blood lymphocyte number and phenotype prior to therapy correlate with response in subcutaneously applied rIL-2 therapy of renal cell carcinoma, Br J Cancer, 66, 1177, 10.1038/bjc.1992.431 Miles, 1992, Induction of soluble tumor necrosis factor receptors during treatment with interleukin-2, Br J Cancer, 66, 1195, 10.1038/bjc.1992.435 Foa, 1992, IL2 treatment for cancer from biology to gene therapy, Br J Cancer, 66, 992, 10.1038/bjc.1992.400 Rosenberg, 1989, Experience with the use of high-dose interleukin-2 on the treatment of 652 cancer patients, Ann Surg, 210, 474, 10.1097/00000658-198910000-00008 Rosenberg, 1985, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N Engl J Med, 313, 1485, 10.1056/NEJM198512053132327 Dillman, 1993, Inpatient continous-infusion interleukin-2 in 788 patients with cancer, Cancer, 71, 2358, 10.1002/1097-0142(19930401)71:7<2358::AID-CNCR2820710730>3.0.CO;2-M Hermann, 1992, Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: Clinical results and immunological effects, Cancer Res, 52, 726 Rosenberg, 1987, A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, N Engl J Med, 316, 889, 10.1056/NEJM198704093161501 Thompson, 1992, Prolonged continous infusion interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma, J Clin Oncol, 10, 960, 10.1200/JCO.1992.10.6.960 Weiss, 1992, A randomized phase II trial of continous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma, J Clin Oncol, 10, 275, 10.1200/JCO.1992.10.2.275 Cameron, 1988, Synergistic antitumor effects of combination immunotherapy with recombinant interlekuin-2 and a recombinant hybrid alpha-interferon on the treatment of established murine hepatic mestastases, Cancer Res, 48, 5810 Rosenberg, 1988, Combination immunotherapy for cancer: Synergistic antitumor interactions of interleukin-2, alpha-interferon and tumor-infiltrating lymphocytes, J Natl Cancer Inst, 80, 1393, 10.1093/jnci/80.17.1393 Greiner, 1987, Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo, Science, 235, 895, 10.1126/science.3580039 Gracomni, 1989, Modulation by recombinant DNA leucocyte (alpha) and fibroblast (beta) interferons by the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells, J Immunol, 133, 1649 Malkovska, 1989, Tumor immunotherapy, Curr Opin Immunol, 1, 883, 10.1016/0952-7915(89)90065-4 Oetggen, 1991, Cytokines in clinical cancer therapy, Curr Opin Immunol, 3, 699, 10.1016/0952-7915(91)90099-M Rosenberg, 1989, Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer, Cancer, 12, 1863 Lee, 1989, Concomitant administration of recombinant human interleukin-2 and recombinant interferon α2A in cancer patients, J Clin Oncol, 7, 1726, 10.1200/JCO.1989.7.11.1726 Huberman, 1991, A phase I study of an outpatient regimen of recombinant human interleukin-2 and alpha-2a-interferon in patients with solid tumors, Cancer, 68, 1708, 10.1002/1097-0142(19911015)68:8<1708::AID-CNCR2820680810>3.0.CO;2-V Fiorentino, 1992, Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer, Br J Cancer, 66, 981, 10.1038/bjc.1992.396 Moormeier, 1991, Interferons: Clinical applications. Hairy cell leukemia, 275 Nathan, 1985, Administration of recombinant interferon-γ to cancer patients enhances monocyte secretion of hydrogen peroxide, 82, 8686 Murray, 1989, In vitro and in vivo activation of human mononuclear phagocytes by gamma interferon: Studies with normal and AIDS monocytes, J Immunol, 138, 2457, 10.4049/jimmunol.138.8.2457 Kirkweed, 1990, In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma, J Clin Oncol, 8, 1070, 10.1200/JCO.1990.8.6.1070 Spriggs, 1988, Recombinant human tumor necrosis factor administered as a 24 hour intravenous infusion. A phase I and pharmacological study, J Natl Cancer Inst, 80, 1039, 10.1093/jnci/80.13.1039 Blay, 1990, Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor, Cancer Res, 50, 2371 Lanz, 1990, Infusion of tumor necrosis factor causes an increase in circulating TNF-binding proteins in humans, Cytokine, 2, 402, 10.1016/1043-4666(90)90048-X Crown, 1991, A phase I trial of recombinant interleukin-1β alone and in combination with myelosuppressive doses of 5-Fluorouracil in patients with gastrointestinal cancer, Blood, 78, 1420, 10.1182/blood.V78.6.1420.1420 Osband, 1990, Effect of autolymphocyte therapy on survival and quality of life on patients with metastatic renal-cell carcinoma, Lancet, 335, 994, 10.1016/0140-6736(90)91064-H Osband, 1989, Autolymphocyte therapy: successful antigen-adoptive immunotherapy following non-specific activation, Clin Res, 37, 469 A Osband, 1989, Autolymphocyte therapy: demonstration of antigen-specific adoptive immunotherapy, Ped Res, 25, 155 A Osband, 1988, Autolymphocyte therapy: previous experience and future prospects, Pathol Immunopathol Res, 7, 483, 10.1159/000157077 Baxevanis, 1988, Enhancement of human T lymphocyte functions by prothymosin α, Immunopharmacology, 15, 73, 10.1016/0162-3109(88)90054-9 Reclos, 1987, Multiple Sclerosis. II Effects of prothymosin α on the autologous and allogeneic MLR in patients with multiple sclerosis, Clin Exp Immunol, 70, 336 Baxevanis, 1987, Prothymosin α restores the depressed autologous and allogeneic mixed lymphocyte reaction in patients with systemic lupus erythematosus, Immunopharmacol Immunotoxicol, 9, 429, 10.3109/08923978709035224 Baxevanis, 1990, Enhancement of human T lymphocyte function by prothymosin α: increased production of IL-2 and expression of IL-2 receptors in normal human peripheral blood T lymphocytes, Immunopharmacol Immunotoxicol, 12, 595, 10.3109/08923979009019679 Frillingos, 1992, Appearance of thymosin al in supernatants of monocytes induced with prothymosin αl, Arch Biochem Biophys, 296, 256, 10.1016/0003-9861(92)90570-M Baxevanis, 1990, Prothymosin-α enhances HLA-DR antigen expression on monocytes from patients with multiple sclerosis, J Neuroimmunol, 27, 141, 10.1016/0165-5728(90)90063-S Baxevanis, 1990, Decreased HLA-DR antigen expression on monocytes causes impaired suppressor cell activity in multiple sclerosis, J Immunol, 144, 4166, 10.4049/jimmunol.144.11.4166 Baxevanis, 1992, Prothymosin α enhances human and murine MHC class II surface antigen expression and messenger RNA accumulation, J Immunol, 148, 1979, 10.4049/jimmunol.148.7.1979 Papanastasiou, 1992, Promotion of murine antitumor activity by prothymosin α treatment: I. Induction of tumoricidal peritoneal cells producing high levels of tumor necrosis factor α, Cancer Immunol Immunother, 35, 145, 10.1007/BF01741862 Baxevanis, 1994, ProTα induces LAK activity in mice, Cancer Immunol Immunother, 38, 181 Livingston, 1982, Specific active immunotherapy in cancer therapy, 363 Bystryn, 1992, Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma, Cancer, 69, 1157, 10.1002/cncr.2820690516 Livingston, 1992, Construction of cancer vaccines with carbohydrate and protein (peptide) tumor antigens, Curr Opin Immunol, 4, 624, 10.1016/0952-7915(92)90038-G Vijaysaradhi, 1991, Purification of an autoantigenic 75-KDa human melanosomal glycoprotein, Int J Cancer, 47, 298, 10.1002/ijc.2910470221 Welt, 1987, Monoclonal antibody to an intracellular antigen images human melanoma transplants in nunu mice, 84, 4200 Burchell, 1989, A short sequence within the amino acid tandem repeat of a cancer associated mucin, contain immunodominant epitopes, Int J Cancer, 44, 691, 10.1002/ijc.2910440423 Shimizu, 1989, Induction of tumor-specific in vivo protective immunity by immunization with tumor antigen-pulsed antigen presenting cells, J Immunol, 142, 1053, 10.4049/jimmunol.142.3.1053 Fearon, 1990, Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response, Cell, 60, 397, 10.1016/0092-8674(90)90591-2 Blankenstein, 1991, Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer, J Exp Med, 173, 1047, 10.1084/jem.173.5.1047 Asher, 1991, Murine tumor cells transduced with the gene for tumor necrosis factor-α, J Immunol, 146, 3227, 10.4049/jimmunol.146.9.3227 Golumbek, 1991, Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4, Science, 254, 713, 10.1126/science.1948050 Tepper, 1989, Murine interleukin-4 displays potent anti-tumor activity in vivo, Cell, 57, 503, 10.1016/0092-8674(89)90925-2 Restifo, 1992, A nonimmunologic sarcoma transduced with the cDNA for interferon γ elicits CD8+ T cells against the wild-type tumor: Correlation with antigen presentation capability, J Exp Med, 175, 1423, 10.1084/jem.175.6.1423 Van Dijk, 1989, Induction of tumor-cell lysis by bispecific monoclonal antibodies and CD3 antigen, Int J Cancer, 43, 344, 10.1002/ijc.2910430230 Segal, 1989, Targeting and activation of cytotoxic lymphocytes, Chem Immunol, 47, 179, 10.1159/000318919 Nitta, 1990, Preliminary trial of specific targeting therapy against malignant glioma, Lancet, 335, 368, 10.1016/0140-6736(90)90205-J Pupa, 1988, Activation of mononuclear cells to be used for hybrid monoclonal antibody-induced lysis of human ovarian carcinoma cells, Int J Cancer, 42, 455, 10.1002/ijc.2910420324 Colnaghi, 1989, Evaluation of the suitability of a monoclonal antibody raised against human ovarian carcinoma for therapeutic approaches, Nucl Med Biol, 16, 633 Reid, 1992, Enhancement of in vitro tumorinfiltrating lymphocyte cytotoxicity by heteroconjugated antibodies, J Immunol, 148, 2630, 10.4049/jimmunol.148.8.2630 Mausfield, 1991, Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody, Cancer Immunol Immunother, 33, 247, 10.1007/BF01744944 Gillies, 1991, Targeting human cytotoxic T lymphocytes to kill heterologous epidermal growth factor receptor-bearing tumor cells, J Immunol, 146, 1067, 10.4049/jimmunol.146.3.1067 Lamers, 1992, Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy, Int J Cancer, 51, 973, 10.1002/ijc.2910510623